Neurocrine Biosciences Inc. (NBIX) is a pioneering biopharmaceutical company headquartered in San Diego, California, United States. Incorporated in 1992, the company has dedicated nearly three decades to discovering and developing innovative therapeutics aimed at improving the lives of patients suffering from neurological and endocrine-related diseases and disorders.
The primary areas of focus for Neurocrine Biosciences are neuroscience and endocrinology. Neurology-focused product candidates seek to address conditions such as Tardive Dyskinesia, Parkinson’s Disease, and Tourette Syndrome while endocrinology-focused treatments are designed for conditions like Congenital Adrenal Hyperplasia and Endometriosis.
The company's portfolio consists of product candidates at various clinical development stages, including INGREZZA® (valbenazine), the first and only FDA-approved treatment for adults with tardive dyskinesia, and ORILISSA® (elagolix), a novel therapy for women's endometriosis pain. These approvals underline the firm's commitment to push boundaries with its medical innovations.
Neurocrine Biosciences operates with a philosophy of pushing scientific boundaries to bring novel therapies to those in need, in order to transform their lives. It integrates cutting-edge science with commercial pragmatism to get life-changing medicines rapidly from lab to patient. The company employs a team of highly skilled professionals from different disciplines necessary for successful drug discovery and development, including biologists, chemists, clinicians, and marketers.
The company's stock is listed on the NASDAQ exchange under the ticker symbol 'NBIX'. It has demonstrated sound performances attracting investors with its health-driven commitment, robust financials, and potential for growth. Over the years, Neurocrine Biosciences has established a strong reputation for its robust pipeline, quality of research, and contribution to medical innovation. The firm's leadership and efforts have set them apart and placed them at the forefront of the biological sciences sector.
Neurocrine Biosciences’ passion for patients and innovative approach to neurology and endocrinology demonstrates not only the value placed on scientific integrity but also the significance of commercial viability. It combines scientific discovery with strategic business acumen, establishing a business model that can successfully translate the best science into the best medicine.